Cheryl R. Blanchard, Ph.D. Email & Phone Number

Bedford, Ma, Us

Anika offers a broad spectrum of therapeutic treatments ranging from osteoarthritis pain management to joint preservation and restoration. Anika provides a full set of sports medicine soft tissue repair solutions and partial and extremities joint implants. Our proprietary regenerative medicine technology is based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body vital for proper joint health and tissue function.

Bedford, Ma, Us

(NASDAQ: ANIK) Commercializes therapeutic products for regenerative medicine in the orthopedic, wound healing, and ophthalmology sectors. Serves on Compensation and Governance/Nominating committees.

Consulting practice serving start-ups, large companies and VC/private equity clients in the biotech and medical devices sector. Services included technology and market assessments, business development, due diligence, strategic planning, and expert witness services in IP, trade secrets, product liability and other legal matters.

Watertown, Ma, Us

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.

San Diego, California, Us

(NASDAQ:DARE) Driven by a mission to accelerate a diverse portfolio of novel therapies for women that expand treatment options, improve outcomes and facilitate convenience.

Plochingen, De

PE-owned, Germany-based developer of orthopedic and industrial ceramic components, including market-leading hip replacement ceramic femoral heads. Provided strategic and leadership guidance through two ownership changes.

Malvern, Pa, Us

(NASDAQ: STIM) Market leader in transcranial magnetic stimulation to treat depression. Serves on Compensation Committee and Nom/Gov Committee.

Venture-backed developer of polymer-controlled drug delivery devices to prevent and treat orthopedic and other surgical bone infections.

Carlsbad, Ca, Us

Spinoff of Integra Life Sciences (NASDAQ: SPNE). a spinal implant and biologics company. Served as Chair, Compensation Committee, and member, Audit Committee.

Recruited by major venture investor to essentially re-start a struggling biotech company developing revolutionary electronic microchip-based implants for controllable, regular drug delivery focused on women’s health (contraception, hormone replacement therapy, osteoporosis) and diabetes. Merged with KeraNetics to add topical drug delivery and regenerative medicine platform to the pipeline.Built world-class executive and company team, raised additional capital, evaluated hundreds of subcutaneous drug delivery markets and solutions to strategically focus on contraceptive drug delivery as most promising near-term technology/product. Developed successful clinical/regulatory FDA strategy and built company value by developing IP portfolio with 32 patent families.Reached a potential $2 billion partnership agreement with Teva Pharmaceuticals (since cancelled) to co-develop multiple drug delivery products, then pursued and secured prestigious non-dilutive $20 million investment from the Bill and Melinda Gates Foundation for an Implantable Long-Acting Reversible Contraception (LARC) product for the foundation’s targeted global initiative.Sold company to Daré Bioscience in 2019 and joined Daré's Board.

Bio2 Technologies has developed Vitrium®, a new class of resorbable orthobiomaterial with broad application in musculo­skeletal surgery. Vitrium differentiates itself from existing biologics and biomaterials by enabling the surgeon to reconstruct bony anatomy without the clinical compromises inherent in currently available technologies. Served as Chair, Compensation Committee. Remains as advisor to company.

Start-up that was developing therapeutic products for osteoarthritis.

San Antonio, Texas, Us

Spun out of earlier work on Keratin-based biotech IP technologies and products at Southwest Research Institute (SwRI).

Warsaw, Indiana, Us

Zimmer was a Global Fortune 500 health care leader in the design, manufacture and distribution of orthopedic implants and other products. Sales then totaled $4.5B with 8,500 employees in 100+ countries. Served as Sr Vice President, corporate officer and member of Zimmer operating committee since 2005. From 2009-2012, as general manager, held full P&L responsibility for $100+ billion biologics business. In corporate role, responsible for research, advanced technologies, clinical, quality and regulatory affairs, and health economics.Built commercial organization that achieved high double-digit biologics sales growth and drove 200% operating profit growth. Delivered successful biologics product launches to build a portfolio of eight novel bone and cartilage repair and joint preservation product families, while identifying disruptive technologies to profitably commercialize antimicrobial, advanced materials, biologics and new therapeutic products. Negotiated/managed strong external partner alliances, including for a new, now-$250M joint preservation product.From 2005-2009, led Global Science and Technology organization spanning 9 BUs and a global organization of 1,300 employees with $150M budget. Responsible for R&D, biologics, medical, quality and regulatory affairs, advanced technologies, medical training, finance and HR in the reconstructive, spine, dental, trauma, biologics, CAS and surgical business units.Drove business strategy and processes to identify unmet health care needs based on outcome-driven innovation, including a Google-like “Innovation Café,” leading to launch of 100+ products that ramped to $500M in new annual revenue. Negotiated multiple licensing and co-development agreements, and partnered on/led acquisitions for 20+ projects. Initiated 40+ clinical trials and 100+ post-market and regulated clinical trials, driving regulatory approval for hundreds of global product launches including medical devices, allograft tissue products and biologics.

Warsaw, Indiana, Us

As Vice President for Corporate Research and Clinical Affairs (2004-2005), and Research and Biologics (2002-2004), led integration of $3.4 billion Centerpulse (formerly Sulzer) acquisition, achieving $300 million in synergies. Also responsible for global corporate research, clinical affairs and biologics with staff of 100+ in the U.S., Europe and Asia Pacific ($60 million budget). Won Zimmer CEO approval to build a new biologics business, then consolidated and delivered 10 years of double-digit growth for what today is a $300 million business. Led new technologies R&D and M&A/licensing pipeline deals, including for game-changing Denovo NT in cartilage repair and Trabecular Metal and Epoch in joint replacement. Served as Research Director from 2000-2002.

Held Zimmer board seat to manage investment and relationship in venture-backed developer of biologics to regenerate and restore function to damaged cartilage and bone.

San Antonio, Tx, Us

For then-$450 million global CRO to industry/government clients, led group of 20 scientists/engineers and lab ops. Responsible for Medical Device and Biologics business unit P&L, contract/licensing negotiations. Performed Ph.D. research on advanced materials at Oak Ridge National Laboratory (NSF grant). Also Adjunct Assistant Professor at The University of Texas Health Science Center, San Antonio, TX.

Ph.D., Materials Science And Engineering

M.S., Materials Science And Engineering

B.S., Ceramic Engineering